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Background and purpose   The Kaplan-Meier (KM) method is 
often used in the analysis of arthroplasty registry data to estimate 
the probability of revision after a primary procedure. In the pres-
ence of a competing risk such as death, KM is known to overes-
timate the probability of revision. We investigated the degree to 
which the risk of revision is overestimated in registry data.
Patients and methods   We compared KM estimates of risk 
of revision with the cumulative incidence function (CIF), which 
takes account of death as a competing risk. We considered revi-
sion by (1) prosthesis type in subjects aged 75–84 years with frac-
tured neck of femur (FNOF), (2) cement use in monoblock pros-
theses for FNOF, and (3) age group in patients undergoing total 
hip arthroplasty (THA) for osteoarthritis (OA).
Results   In 5,802 subjects aged 75–84 years with a monoblock 
prosthesis for FNOF, the estimated risk of revision at 5 years 
was 6.3% by KM and 4.3% by CIF, a relative difference (RD) of 
46%. In 9,821 subjects of all ages receiving an Austin Moore (non-
cemented) prosthesis for FNOF, the RD at 5 years was 52% and 
for 3,116 subjects with a Thompson (cemented) prosthesis, the RD 
was 79%. In 44,365 subjects with a THA for OA who were less 
than 70 years old, the RD was just 1.4%; for 47,430 subjects > 70 
years of age, the RD was 4.6% at 5 years.
Interpretation   The Kaplan-Meier method substantially over-
estimated the risk of revision compared to estimates using com-
peting risk methods when the risk of death was high. The bias 
increased with time as the incidence of the competing risk of death 
increased. Registries should adopt methods of analysis appropri-
ate to the nature of their data.
 
Arthroplasty registries typically present results of joint replace-
ment in terms of the Kaplan-Meier (KM) estimates of the sur-
vival of the primary prosthesis. The estimates are interpreted 
as the probability of the prosthesis surviving until a nominated 
time after implantation. Alternatively, a registry may quote the 
complement  (in  probability)  of  the  KM  survivorship  func-
tion. In the Australian Orthopaedic Association National Joint 
Replacement Registry (AOA NJRR) (AOANJRR 2009), this 
latter measure of revision is termed the “cumulative per cent 
revision” (CPR).
A registry follows up patients from the date of the primary 
procedure until the date of statistical analysis. The observation 
time of a patient who has undergone a primary procedure but 
who has not had a revision by the date of analysis is said to 
be right censored at that date. We do not know when, in the 
future, that patient may undergo a revision. All we know is 
that it has not happened yet, and the KM method takes that 
into account using all the information on that patient up until 
the date of censoring. Crucially, the KM method assumes that 
patients whose time is censored will have the same chance 
of revision at any subsequent time as those whose time is not 
censored. In a sense, censoring is an inconvenience that pre-
vents us from seeing what may happen in the future.
The problem with the use of the KM method in the analysis 
of registry data is that deaths are handled in exactly the same 
way: the patient’s follow-up time is right censored at the time of 
death. However, death differs from censoring in that it does not 
merely conceal the occurrence of a future revision, it changes 
the probability of revision occurring. Essentially, under the KM 
method we are assuming that dead patients will have the same 
chance of eventually having a revision as those still living.
When a patient is at risk of experiencing multiple events, 
with each precluding the other events or altering the probabil-
ity of occurrence of the other events, these events are called 
competing risks (Gooley et al. 1999). Death changes the prob-
ability of a patient’s prosthesis being revised and is said to be 
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revision is a competing risk to death as it precludes the occur-
rence of death as a first event.
The above mentioned problem with the KM method has 
sometimes been approached by pretending that the compet-
ing event, in this case death, can be removed and by assuming 
that the revision rate is unaffected by this. However, since it 
is impossible to know from the data at hand how removing 
one outcome would affect the outcome of the other event(s), 
this is purely speculative (Prentice et al. 1978, Andersen et 
al. 2002). Furthermore, since there is a negative correlation 
between the likelihood of undergoing a revision and death, the 
2 events are not independent. The implication of the violation 
of the KM assumptions is that the KM estimates in the pres-
ence of competing risks do not have a meaningful probability 
interpretation (Andersen et al. 2002); that is, the KM estimate 
of revision is not a valid estimate of the probability of revision 
assuming that the patient does not die.
Kalbfleisch and Prentice (1980) have developed a method 
for estimating the probability of revision in the competing 
risks situation, based on a measure called the cumulative inci-
dence function (CIF). The CIF for revision at any time depends 
on both the number of patients who have been revised and 
the number of patients who have not experienced any event 
(death or revision) by that time. Hence, when the CIF is used 
to estimate the probability of revision, the probability of death 
is taken into account. Patients who have neither died nor been 
revised by the date of analysis are treated as right censored, 
just as with the KM method.
In the presence of a competing risk such as death, the stan-
dard KM method will always overestimate the true revision 
rate (Biau et al. 2007, Putter et al. 2007). If the death rate is 
low, then the bias in estimating the risk of revision using KM 
is small. But in elderly and frail patients, or in registry data 
where long-term observation is the goal, the competing risk of 
death becomes greater and the magnitude of the KM overesti-
mate of revision will become more substantial.
In  this  study,  we  applied  methods  of  competing  risk  to 
data from large cohorts of patients in the AOA National Joint 
Replacement Registry and contrasted the results with those 
obtained from the standard Kaplan-Meier method.
Materials and methods
Material
Data for this study were obtained from the Australian Ortho-
paedic  Association  National  Joint  Replacement  Registry 
(AOA NJRR). The registry was established and began data col-
lection in 1999, and achieved full national coverage in 2002. 
The AOA NJRR now has data on 550,000 procedures. Almost 
100% of hip and knee procedures performed in Australia are 
captured. Mortality data in the AOA NJRR are obtained from 
the National Death Index, a database maintained by the Aus-
tralian Institute of Health and Welfare.
Our data consisted of records of patients who received par-
tial or total arthroplasty for fractured neck of femur (FNOF) 
and of patients who received total hip arthroplasty (THA) for 
osteoarthritis (OA) in the 7-year period from January 1, 2002 to 
December 31, 2008. We chose 3 areas of interest for our anal-
ysis. In the FNOF group, we examined results from 2 subsets 
of data. In the first, we compared results from 4 main types of 
prostheses (monoblock, unipolar modular, bipolar, and THA) 
in the age group 75–84 years; in the second, we compared 
results  from  2  types  of  monoblock  prostheses  (cementless 
Austin Moore and cemented Thompson) in all ages. For our 
third set of analyses, based on patients with osteoarthritis who 
underwent THA, we compared results from patients younger 
than 70 years with results from patients who were 70 years or 
older. For all analyses, we excluded patients who had bilateral 
procedures. Revisions are reoperations of primary hip replace-
ments and involve removal and/or replacement of one or more 
component used in the primary procedure.
Statistics 
The outcome of interest was “time to first revision”, being 
the time interval between the date of insertion of the primary 
prosthesis and the date of revision. We used standard Kaplan-
Meier survival analysis to calculate the cumulative per cent of 
primary procedures revised (CPR) (the Kaplan-Meier (KM) 
estimates). To take account of the competing risk of death, 
we calculated the cumulative incidence function (CIF). Confi-
dence intervals for the CPR were based on a method developed 
by Kalbfleisch and Prentice (1980) and the confidence inter-
vals for the CIF were based on the method of Aalen (1978).
In the non-competing risk paradigm, we used the log-rank 
test to test for differences in CPR, and in the competing risk 
paradigm  we  used  Gray’s  test  (1988)  to  compare  the  CIF 
between groups.
In order to give an indication of the magnitude of the over-
estimation (that is, the bias) of the KM estimate, we calculated 
the difference of the KM and CIF estimates, and the per cent 
relative difference (RD): 
  (KM estimate – CIF estimate)
RD =  ––––––––––––––––––––––––  × 100
               CIF estimate
The estimates of CPR, CIF, difference, and RD are dis-
played in graphs and tables. As recommended when dealing 
with competing risks, we show plots of mortality and also of 
revisions (Dignam and Kocherginsky 2008). Plots were cur-
tailed when the number at risk became small (Tables 2, 3, 
and 4), following the conventions adopted in the Australian 
Registry’s Annual Report (AOANJRR 2009) (p3) and those 
recommended by Pocock et al. (2002). However, for the test 
statistics we used all available data.550  Acta Orthopaedica 2010; 81 (5): 548–555
Results
The distributions of outcomes (censoring, revision, and death) 
for patients in the 3 groups of interest are presented in Table 
1. Note that the percentage revised shown in this table is the 
simple raw percentage for descriptive purposes, and not the 
KM or CIF estimate.
Figure 1 shows the KM and CIF estimates for revision for 
the 4 types of prosthesis in patients with FNOF in the 75–84-
year age group. The KM estimates were higher than the CIF 
estimates at each time point for each type of prosthesis (Table 
2). The KM and CIF estimates for death are shown in Figure 2. 
Patients with monoblock prostheses had the highest probabil-
ity of death. The KM and CIF estimates of death were almost 
identical but in all cases the KM estimate exceeded the CIF.
The  second  group  of  interest  was  patients  who  received 
either  cementless  Austin  Moore  prostheses  or  cemented 
Thompson prostheses after FNOF. The KM and CIF estimates 
in Figure 4 again reveal that the KM method overestimated 
the risk of revision compared to the CIF in this population. 
The estimates for revision for each year were highest for those 
patients who received Austin Moore cementless prostheses 
(Table 3), but after 5 years the KM method overestimated the 
risk of revision by more than 2% for both types of prosthe-
sis, and the relative biases were substantial. As can be seen 
in Figure 5, patients with Austin Moore prostheses had the 
highest mortality in the study period. Both the log-rank test 
and Gray’s test were significant for difference in revision (p < 
0.001) and for difference in death (p < 0.001).
Table 1. Distribution of outcomes for the three study groups
  Censored a  Revised b  Deceased  Total
FNOF, prosthesis types 
(75–84 years of age)
  Monoblock  2,348 (40%)  225 (4%)  3,229 (56%)  5,802
  Unipolar  2,521 (70%)  98 (3%)  990 (27%)  3,609
  Bipolar  1,921 (62%)  73 (2%)  1,114 (36%)  3,108
  THA  1,373 (76%)  64 (4%)  368 (20%)  1,805
  Total  8,163 (57%)  460 (3%)  5,701 (40%)  14,324
FNOF, monoblock       
(all ages) 
  Austin Moore  3,310 (34%)  369 (4%)  6,142 (63%)  9,821
  Thompson  1,283 (41%)  75 (2%)  1,758 (56%)  3,116
  Total  4,593 (36%)  444 (3%)  7,901 (61%)  12,937
OA, THA       
  Age < 70 years  42,136 (95%)  1,149 (3%)  1,080 (2%)    44,365
  Age ≥ 70 years  41,623 (88%)  1,189 (3%)  4,618 (10%)  47,430
  Total  83,759 (91%)  2,338 (3%)  5,698 (6%)    91,795
a right censored due to closure of database for analysis.
b simple raw proportion, not allowing for censoring. 
FNOF: fractured neck of femur; OA: osteoarthritis; THA: total hip arthroplasty.
The difference in the KM and CIF esti-
mates of revision was most pronounced 
for the monoblock prostheses, the group 
with the highest mortality, and least for 
THA, the group with the lowest mortal-
ity (Table 2 and Figure 2). In all groups, 
the bias in the KM estimation increased 
with time as the competing risk of death 
increased (Figure 3).
The global tests (log-rank test for KM 
estimates and Gray’s test for CIF estimates) 
comparing revision across all four types of 
prostheses were statistically significant (p 
< 0.001 and p = 0.001, respectively). The 
log-rank test and Gray’s test gave the same 
results for tests between specific pairs of 
prostheses in all but one of the compari-
sons. The log-rank test for the difference 
in  revision  rate  between  monoblock  and 
unipolar  prostheses  was  significant  (p  = 
0.006), but the Gray’s test for difference 
between the CIFs was not (p = 0.1).
Figure 1. Estimates of revision by type of prosthesis in patients with FNOF who 
were aged 75–84 years.
Figure 2. Estimates of death by type of prosthesis in patients with FNOF who 
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Table 2. Per cent estimates (with 95% confidence interval) of revision in patients aged 75–84 years with FNOF
    1 year  2 years  3 years  4 years  5 years  6 years
Monoblock           
  At risk  3,512  2,521  1,759  1,108  599  266
  KM a  3.2 (2.7–3.8)  4.6 (4.0–5.3)  5.6 (4.9–6.5)  5.9 (5.1–6.8)  6.3 (5.5–7.3)  6.6 (5.6–7.8)
  CIF b  2.6 (2.2–3.1)  3.5 (3.1–4.1)  4.1 (3.6–4.6)  4.2 (3.7–4.8)  4.3 (3.8–4.9)  4.4 (3.9–5.0)
  Diff. c  0.6  1.1  1.5  1.7  2.0  2.2
  RD d  21%  30%  38%  40%  46%  50%
Unipolar           
  At risk  2,180  1,376  805  439  223  71
  KM  2.1 (1.6–2.7)  3.1 (2.5–3.9)  3.9 (3.1–4.8)  4.8 (3.7–6.0)  5.6 (4.3–7.3)  6.0 (4.5–8.0)
  CIF  1.9 (1.5–2.4)  2.7 (2.1–3.3)  3.2 (2.6–4.0)  3.8 (3.0–4.7)  4.3 (3.3–5.3)  4.5 (3.5–5.7)
  Diff.  0.2  0.4  0.6  1.0  1.3  1.5
  RD  10%  15%  20%  26%  31%  34%
Bipolar           
  At risk  2,351  1,868  1,398  951  553  245
  KM  1.6 (1.2–2.1)  2.3 (1.7–2.9)  2.7 (2.1–3.5)  3.2 (2.5–4.1)  3.4 (2.6–4.3)  3.4 (2.6–4.3)
  CIF  1.5 (1.1–1.9)  2.0 (1.5–2.6)  2.3 (1.8–2.9)  2.7 (2.1–3.3)  2.7 (2.2–3.4)  2.7 (2.2–3.4)
  Diff.  0.1  0.3  0.4  0.6  0.6  0.6
  RD  9%  14%  17%  21%  23%  23%
THA           
  At risk  1,238  873  598  379  215  93
  KM  2.8 (2.1–3.8)  3.5 (2.7–4.6)  3.9 (3.0–5.1)  4.8 (3.6–6.4)  5.8 (4.3–8.0)  6.5 (4.7–9.1)
  CIF  2.7 (2.0–3.6)  3.3 (2.5–4.3)  3.7 (2.8–4.7)  4.3 (3.3–5.6)  5.0 (3.7–6.6)  5.4 (4.0–7.2)
  Diff.  0.1  0.2  0.3  0.5  0.8  1.1
  RD  4%  6%  8%  12%  17%  20%
a Kaplan-Meier estimate of cumulative per cent revised.
b Cumulative incidence function.
c Difference (bias of the KM estimate).
d Relative difference (bias of KM estimate relative to the CIF).
Results  from  the  third  study  group,  which  consisted  of 
patients who received THA as treatment for OA, are pre-
sented in Figures 6 and 7 and in Table 4. The KM estimates 
in the older age group (70 years and over) increased slightly 
more with time than the CIF estimates, whereas the KM 
and CIF estimates in the younger age group (less than 70 
years) were very similar. There was no significant difference 
between the two age groups with respect to revision (Gray’s 
test, p = 0.2), whereas the risk of death was of course higher 
in the 70-year and older age group (Gray’s test, p < 0.001). 
Overall,  the  risk  of  death  in  this  group  was  substantially 
lower than in the 2 other study groups (Figures 2 and 5): the 
competing risk of death was less and so the bias of the KM 
estimate was less.
Discussion
We  have  shown  using  data  from  the AOA  National  Joint 
Replacement Registry that the KM method overestimated the 
risk of revision compared to the CIF estimates, and that this 
was most pronounced when the incidence of the competing 
risk (death) was high. Furthermore, with time the difference 
and relative difference between the 2 estimates increased as 
the incidence of death increased (Figure 3).
In  most  of  the  instances  where  we  compared  revisions 
between  groups—for  example,  age  groups  or  prosthesis 
type—if the KM estimate was higher in one group than in 
another, so too (in general) would the CIF be. But this was not 
always the case, and it depended on the distribution of deaths 
in the groups being compared. Statistical tests for differences 
in estimates between groups may also yield different results. 
Figure 3. Relative overestimation of KM estimates compared to CIF estimates 
by years after primary procedure and type of prosthesis; patients were aged 
75–84 years with FNOF.552  Acta Orthopaedica 2010; 81 (5): 548–555
Figure 5. Estimates of death by type of prosthesis (cementless Austin Moore 
vs. cemented Thompson) in patients with FNOF. 
Table 3. Per cent estimates (with 95% confidence interval) of revision in patients with FNOF who received Austin-Moore or 
Thompson prostheses
    1 year  2 years  3 years  4 years  5 years  6 years
Austin Moore stem           
  At risk  5,514  3,893  2,756  1,740  963  403
  KM a  3.4 (3.0–3.8)  4.7 (4.2–5.3)  5.5 (4.9–6.1)  5.7 (5.2–6.4)  6.2 (5.6–7.0)  6.5 (5.8–7.4)
  CIF b  2.7 (2.4–3.1)  3.5 (3.1–3.9)  3.8 (3.5–4.3)  3.9 (3.6–4.4)  4.1 (3.7–4.5)  4.2 (3.8–4.6)
  Diff. c   0.7  1.2  1.6  1.8  2.1  2.4
  RD d  25%  35%  42%  45%  52%  57%
Thompson stem           
  At risk  1,905  1,334  865  506  230  96
  KM  1.5 (1.1–2.1)  2.5 (1.9–3.3)  3.4 (2.6–4.4)  4.1 (3.2–5.3)  5.6 (4.1–7.5)  5.6 (4.1–7.5)
  CIF  1.3 (0.9–1.7)  1.9 (1.5–2.5)  2.3 (1.8–3.0)  2.6 (2.1–3.3)  3.1 (2.4–3.9)  3.1 (2.4–3.9)
  Diff.  0.3  0.6  1.1  1.5  2.5  2.5
  RD  20%  33%  44%  56%  79%  79%
 
a Kaplan-Meier estimate of cumulative per cent revised.
b Cumulative incidence function. 
c Difference (bias of the KM estimate).
d Relative difference (bias of KM estimate relative to the CIF).
Figure 6. Estimates of revision by age group in patients with OA and THA. Figure 7. Estimates of death by age group in patients with OA and THA.
Figure 4. Estimates of revision by type of prosthesis (cementless Austin Moore 
vs. cemented Thompson) in patients with FNOF.Acta Orthopaedica 2010; 81 (5): 548–555  553
This is illustrated in the comparison of revisions of monoblock 
with unipolar prostheses in the 75–84-year age group (Figure 
1). The log-rank test for difference in KM estimates was statis-
tically significant whereas the Gray’s test for difference in CIF 
estimates was not. This is because patients with monoblock 
prostheses had higher mortality than patients with unipolar 
prostheses (Figure 2) and the CIF estimate depends on both 
the event of interest and the competing event, whereas the KM 
estimate depends only on the event of interest. It follows that 
in the presence of competing risks, it is important to interpret 
the CIF estimates of the event of interest together with the CIF 
of the competing event. The CIF estimate may be low for one 
event because the failure rate for the competing event is high, 
leading to fewer subjects being left to experience the event of 
interest. This implies that one has to be cautious when apply-
ing results from competing risks analysis on one population to 
another population with a possible difference in incidence of 
the competing risks.
Our work has not taken in to account other possible compet-
ing risks for the event of interest—revision—but to the extent 
that they may be present and unaccounted for, our estimates 
of the KM bias are conservative. Also, we have not considered 
selection of patients by surgeons on clinical grounds or other 
characteristics and the biases that may have arisen from that—
but neither does the standard KM estimate.
There has been infrequent use of competing risk analysis 
in orthopedic research. In a study of a real data set and a fic-
titious data set of hip arthroplasty, Schwarzer et al. (2001) 
concluded that death should be treated as a competing risk 
in the analysis, and that the CIF should be used instead of 
the KM estimate (CPR) to calculate the probability of revi-
sion. Biau et al. (2007) discussed the use of the Kaplan-Meier 
method and the cumulative incidence function to estimate the 
survival of hip and knee arthroplasty. More recently, Ranstam 
and Robertsson (2010) from the Swedish Knee Arthroplasty 
Register have discussed the problem of competing risks as 
part of a general summary of issues facing statistical analysis 
of registry data. Using simulated data and a cohort (n=406) 
of patients undergoing total hip replacement, Fennema and 
Lubsen (2010) examined the bias of the KM estimate and rec-
ommended use of the cumulative incidence in the presence of 
competing risks.
Competing risk methodology is being increasingly applied 
to other areas of medical research (Kim et al. 2006, Resche-
Rigon et al. 2006, Beyersmann et al. 2007, Wolbers et al. 
2009, Evans et al. 2010). One of the limitations in performing 
competing risks analysis has been the lack of readily avail-
able software. This is now changing: Stata has user-written 
programs for calculating the CIF for competing risks (Covi-
ello and Boggess 2002). The “R” package “cmprsk” contains 
commands  for  calculating  the  CIF  and  performing  Gray’s 
k-sample test. SAS macros also exist for estimating the CIF 
and performing Gray’s test (Moeschberger et al. 2008). 
We used only non-parametric methods to estimate the risk 
of revision in the selected population, as the main goal was 
to illustrate how the standard KM method overestimates the 
risk of revision in the presence of a competing risk. Model-
ing techniques that allow direct comparisons of the cumulative 
incidence function adjusting for covariates are now also avail-
able (Fine and Gray 1999, Klein and Andersen 2005, Zhang 
and Fine 2008), and we have planned the application of these 
methods to joint registry data for a later study.
In our data, the differences between the KM and CIF esti-
mates in the 2 FNOF groups were evident after a relatively 
short time. Scope for further research would entail applying 
competing  risks  methodology  to  joint  replacement  registry 
data on patients with lower mortality rates such as in the THA, 
OA group, but with a much longer follow-up time—where 
Table 4. Per cent estimates (with 95% confidence interval) of revision in patients with osteoarthritis who underwent total 
hip replacement–by age group
    1 year  2 years  3 years  4 years  5 years  6 years
Age < 70 years           
  At risk  35,335  27,994  21,454  15,322  9,737  4,714
  KM a  1.4 (1.3–1.5)  2.1 (2.0–2.3)  2.7 (2.5–2.8)  3.0 (2.9–3.2)  3.6 (3.4–3.8)  4.1 (3.9–4.4)
  CIF b  1.4 (1.3–1.5)  2.1 (2.0–2.3)  2.6 (2.5–2.8)  3.0 (2.8,3.2)  3.5 (3.3–3.7)  4.1 (3.8–4.4)
  Diff. c  0.003  0.01  0.02  0.03  0.05  0.07
  RD d  0.3%  0.5%  0.8%  1.0%  1.4%  1.8%
Age ≥ 70 years           
  At risk  38,089  30,254  22,853  16,141  10,059  4,636
  KM  1.6 (1.5–1.7)  2.1 (2.0–2.3)  2.5 (2.4–2.7)  2.9 (2.8–3.1)  3.3 (3.1–3.5)  3.7 (3.5–4.0)
  CIF  1.6 (1.5–1.7)  2.1 (2.0–2.2)  2.5 (2.3–2.6)  2.8 (2.7–3.0)  3.2 (3.0–3.4)  3.5 (3.3–3.7)
  Diff.  0.01  0.03  0.06  0.10  0.15  0.22
  RD  0.9%  1.4%  2.3%  3.4%  4.6%  6.2%
 
a Kaplan-Meier estimate of cumulative per cent revised.
b Cumulative incidence function. 
c Difference (bias of the KM estimate).
d Relative difference (bias of KM estimate relative to the CIF.554  Acta Orthopaedica 2010; 81 (5): 548–555
death as a competing risk would thus become more important. 
Another application of competing risk methods to arthroplasty 
data is in the analysis of cause-specific revisions, where each 
cause (infection, dislocation, loosening, etc.) acts as a compet-
ing risk to every other cause. If the revision rate due to some 
of these competing causes of risk is high, the bias of the KM 
estimate would be considerable. However, in the present study 
where the revision rate was low, if death were not to be consid-
ered a competing risk event, we would expect the difference 
between the KM and CIF estimates for the different causes of 
revision to be negligible.
How, then, should clinicians and other readers interpret the 
results currently published in registry reports, given that the 
Kaplan-Meier method is used in all national collections? The 
answer must be “cautiously”. In older patients, in analyses 
of revisions in frail patients and when a registry has a long 
follow-up time, caution should be greatest, as overestimation 
of risk will be highest because of the high incidence of death. 
Health services planners using estimates of revision from reg-
istry reports to project service use and costs should consult the 
relevant registry and seek statistical advice.
Competing risks present arthroplasty registries with at least 
3 related problems. First, the methods of analysis currently 
being used are known to be inappropriate. Second, the inter-
pretation of KM estimates in the presence of competing risks 
is difficult. Third, risks of revision may be substantially biased 
(although in certain circumstances, for many analyses the bias 
of the KM method will be small and the conclusions will not 
change). As a result of these problems, registries may be open 
to criticism from industry, regulatory bodies, and other stake-
holders, and this may compromise the undoubted usefulness 
of the registries.
How should registries respond? They are now aware of the 
concept of competing risk and the problems of the KM esti-
mate. Indeed, for several years the Swedish Knee Arthroplasty 
Register has advised readers of their Annual Reports of the 
bias  in  published  KM  estimates  (SKAR  2008).  However, 
because of the long and successful histories of many national 
collections, including the AOA NJRR, and the familiarity of 
their stakeholders with traditional methods of analysis and 
presentation, registries have yet to adopt the newer methods. 
What is needed now is a cooperative effort across all national 
arthroplasty registries to update their analytical approaches to 
be in line with current statistical knowledge, coupled with a 
well-planned and targeted education process for those who 
make use of the information provided by the registries.
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